Want to see IN:AJANTPHARM full AI Analyst Report?
AJANTPHARM Stock Chart & Stats
₹3366.45
₹16.60(0.49%)
At close: 4:00 PM EDT
₹3366.45
₹16.60(0.49%)
Day’s Range― - ―
52-Week Range₹2,335.00 - ₹3,598.40
Previous CloseN/A
Volume81.90K
Average Volume (3M)2.10K
Market Cap
₹433.54B
Enterprise Value₹346.33K
Total Cash (Recent Filing)₹6.65B
Total Debt (Recent Filing)₹2.60B
Price to Earnings (P/E)38.1
Beta0.40
Next Earnings
Nov 04, 2026EPS Estimate
23.05Next Dividend Ex-DateN/A
Dividend Yield0.81%
Share Statistics
EPS (TTM)84.53
Shares Outstanding124,935,620
10 Day Avg. Volume2,991
30 Day Avg. Volume2,099
Financial Highlights & Ratios
PEG Ratio2.23
Price to Book (P/B)7.74
Price to Sales (P/S)6.43
P/FCF Ratio231.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)98.72
Revenue Forecast (FY)₹62.83B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetA very conservative balance sheet with low leverage provides long-term financial flexibility to fund R&D, geographic expansion or weather cyclical downturns. Sustained low debt supports capital allocation optionality, lowers default risk, and underpins consistent returns on equity over time.
Consistent Revenue Growth And Strong ProfitabilityMulti-year revenue growth paired with historically healthy net margins indicates durable demand for branded products and effective cost control. Persistent profitability supports reinvestment, product development and shareholder returns, making core earnings less susceptible to short-term volatility.
Diversified Branded Generics And International FootprintA diversified portfolio across ophthalmology, dermatology, cardiology and other areas plus domestic and international channels reduces dependence on any single market or product. This structural diversification stabilizes revenue and supports scalable marketing and regulatory investments.
Bears Say
Volatile And Weakening Cash ConversionMaterial weakening in operating cash flow and a sharp drop in free cash flow reduce predictability of internal funding for capex, launches, or dividends. Persistent working-capital swings would constrain long-term reinvestment and increase reliance on external financing during growth phases.
Margin Compression In FY2026A notable decline in gross and operating margins suggests pressure from cost inflation, adverse mix, or pricing competition. If structural, margin erosion can impair cash generation and ROE, forcing either price increases or cost restructuring that may take multiple quarters to restore.
Dependence On Product Approvals, Launches And FXReliance on timely regulatory approvals and successful launches creates binary execution risk for medium-term growth. Combined export FX sensitivity means macrocurrency moves can materially affect reported revenue and margins, complicating forward planning and predictable cash flows.
Ajanta Pharma Limited News
AJANTPHARM FAQ
What was Ajanta Pharma Limited’s price range in the past 12 months?
Ajanta Pharma Limited lowest stock price was ₹2335.00 and its highest was ₹3598.40 in the past 12 months.
What is Ajanta Pharma Limited’s market cap?
Ajanta Pharma Limited’s market cap is ₹433.54B.
When is Ajanta Pharma Limited’s upcoming earnings report date?
Ajanta Pharma Limited’s upcoming earnings report date is Nov 04, 2026 which is in 87 days.
How were Ajanta Pharma Limited’s earnings last quarter?
Ajanta Pharma Limited released its earnings results on Jul 30, 2026. The company reported ₹26.72 earnings per share for the quarter, beating the consensus estimate of ₹23.04 by ₹3.68.
Is Ajanta Pharma Limited overvalued?
According to Wall Street analysts Ajanta Pharma Limited’s price is currently Overvalued.
Does Ajanta Pharma Limited pay dividends?
Ajanta Pharma Limited pays a Annually dividend of ₹32 which represents an annual dividend yield of 0.81%. See more information on Ajanta Pharma Limited dividends here
What is Ajanta Pharma Limited’s EPS estimate?
Ajanta Pharma Limited’s EPS estimate is 23.05.
How many shares outstanding does Ajanta Pharma Limited have?
Ajanta Pharma Limited has 124,935,620 shares outstanding.
What happened to Ajanta Pharma Limited’s price movement after its last earnings report?
Ajanta Pharma Limited reported an EPS of ₹26.72 in its last earnings report, beating expectations of ₹23.04. Following the earnings report the stock price went up 0.935%.
Which hedge fund is a major shareholder of Ajanta Pharma Limited?
Currently, no hedge funds are holding shares in IN:AJANTPHARM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ajanta Pharma Limited
Established in 1973 and headquartered in Mumbai, India, Ajanta Pharma Limited operates as a specialized pharmaceutical enterprise. This company, along with its subsidiaries, is dedicated to the development, manufacturing, and commercialization of finished dosage forms. Its extensive product range caters to numerous therapeutic categories, such as anti-infectives (antibiotic, anti-malarial), chronic disease management (anti-diabetic, cardiology), women's health (gynecology), pediatrics, respiratory ailments, general health, dermatology, ophthalmology, and pain management. Notable products include multivitamins, antibiotics, eye drops, and cough syrups. Ajanta Pharma boasts a substantial international footprint, operating across India, Africa, other parts of Asia, the United States, and additional global markets. Furthermore, it supplies its pharmaceutical offerings to various government entities, including armed forces, public hospitals, and governmental procurement departments.
Technical Analysis
Emcure Pharmaceuticals Limited
―
Glenmark Pharmaceuticals Limited
―
IPCA Laboratories Limited
―
―
Wockhardt Limited
―